Marc Sanson

Summary

Country: France

Publications

  1. ncbi [Gliomatosis cerebri]
    M Sanson
    Fédération de Neurologie Mazarin, Groupe Hospitalier Pitié Salpêtrière et Université Pierre et Marie Curie, 75013 Paris
    Rev Neurol (Paris) 161:173-81. 2005
  2. ncbi IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    C Houillier
    Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié Salpêtrière AP HP, Paris, France
    Neurology 75:1560-6. 2010
  3. ncbi Molecular changes in brain tumors: prognostic and therapeutic impact
    Marc Sanson
    INSERM U711 and Service de Neurologie, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Curr Opin Oncol 18:623-30. 2006
  4. ncbi Initial chemotherapy in gliomatosis cerebri
    M Sanson
    Fédération de Neurologie Mazarin, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    Neurology 63:270-5. 2004
  5. ncbi Molecular changes in gliomas
    Marc Sanson
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Paris, France
    Curr Opin Oncol 16:607-13. 2004
  6. ncbi Oligodendrogliomas: an update on basic and clinical research
    Marc Sanson
    Inserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Curr Neurol Neurosci Rep 3:223-8. 2003
  7. ncbi [Improving the prognosis of glioma]
    Marc Sanson
    , , Paris (75
    Presse Med 33:1267. 2004
  8. ncbi Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas
    Marc Sanson
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    J Neurosurg 97:1397-401. 2002
  9. ncbi Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951
    Karima Mokhtari
    Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research Pierre and Marie Curie University, Pitie Salpetriere Group Hospital, Paris, France
    Cancer 117:3014-26. 2011
  10. ncbi Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas
    Marc Sanson
    L Institut National de la Santé et de la Recherche Médicale U711, Fédération de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 75651, Paris Cedex 13, France
    J Clin Oncol 27:4150-4. 2009

Detail Information

Publications101 found, 100 shown here

  1. ncbi [Gliomatosis cerebri]
    M Sanson
    Fédération de Neurologie Mazarin, Groupe Hospitalier Pitié Salpêtrière et Université Pierre et Marie Curie, 75013 Paris
    Rev Neurol (Paris) 161:173-81. 2005
    ..Diagnosis and management of GC are difficult. Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable and large field radiotherapy carries the risk of severe toxicity...
  2. ncbi IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    C Houillier
    Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié Salpêtrière AP HP, Paris, France
    Neurology 75:1560-6. 2010
    ..Recent studies have shown that IDH1 and IDH2 mutations occur frequently in gliomas, including low-grade gliomas. However, their impact on the prognosis and chemosensitivity of low-grade gliomas remains unclear...
  3. ncbi Molecular changes in brain tumors: prognostic and therapeutic impact
    Marc Sanson
    INSERM U711 and Service de Neurologie, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Curr Opin Oncol 18:623-30. 2006
    ..This review focuses on recent advances in the molecular biology of the main primary brain tumors (gliomas, medulloblastomas, and ependymomas), with particular emphasis on prognostic markers and potential therapeutic targets...
  4. ncbi Initial chemotherapy in gliomatosis cerebri
    M Sanson
    Fédération de Neurologie Mazarin, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    Neurology 63:270-5. 2004
    ..Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity. In this setting, initial chemotherapy warrants further investigation...
  5. ncbi Molecular changes in gliomas
    Marc Sanson
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Paris, France
    Curr Opin Oncol 16:607-13. 2004
    ....
  6. ncbi Oligodendrogliomas: an update on basic and clinical research
    Marc Sanson
    Inserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Curr Neurol Neurosci Rep 3:223-8. 2003
    ..There is little doubt that these emerging techniques will be very helpful in clinical practice for refining both classification and therapeutic indications of oligodendroglial tumors...
  7. ncbi [Improving the prognosis of glioma]
    Marc Sanson
    , , Paris (75
    Presse Med 33:1267. 2004
  8. ncbi Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas
    Marc Sanson
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    J Neurosurg 97:1397-401. 2002
    ..Chromosomal deletions of 10q and candidate genes such as PTEN and DMBT1 have been thoroughly investigated in glioblastomas but few data specifically address oligodendrogliomas...
  9. ncbi Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951
    Karima Mokhtari
    Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research Pierre and Marie Curie University, Pitie Salpetriere Group Hospital, Paris, France
    Cancer 117:3014-26. 2011
    ....
  10. ncbi Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas
    Marc Sanson
    L Institut National de la Santé et de la Recherche Médicale U711, Fédération de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 75651, Paris Cedex 13, France
    J Clin Oncol 27:4150-4. 2009
    ..Unexpected mutations affecting the isocitrate dehydrogenase (IDH1) gene at codon 132 have been found in 12% of glioblastomas...
  11. ncbi MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
    Emmanuelle Criniere
    INSERM, U711, Biologie des Interactions Neurones and Glie, Universite Pierre et Marie Curie, Faculte de Medecine, Paris, France
    J Neurooncol 83:173-9. 2007
    ..001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression...
  12. ncbi MGMT methylation: a marker of response to temozolomide in low-grade gliomas
    Sibille Everhard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 60:740-3. 2006
    ..0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies...
  13. ncbi Prognostic impact of molecular markers in a series of 220 primary glioblastomas
    Caroline Houillier
    Mazarin Neurology Service and INSERM U711, Biology of Neuronal and Glial Interactions, Paris, France
    Cancer 106:2218-23. 2006
    ..02). CONCLUSION: Despite their limited prognostic impact, the genetic markers investigated here outline distinct molecular pathways involved in glioblastoma tumorigenesis and warrant broader molecular screening...
  14. ncbi Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors
    Ahmed Idbaih
    INSERM, Unité 711, Paris, Universite Pierre et Marie Curie PARIS6, Laboratoire Biologie des Interactions Neurone Glie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Brain Res 1198:16-20. 2008
    ..Finally, MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors...
  15. ncbi Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma
    François Ducray
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013, Paris, France
    J Neurooncol 101:457-62. 2011
    ..Further investigation is needed to determine whether this treatment is preferable to initial radiation therapy...
  16. ncbi BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas
    Ahmed Idbaih
    INSERM, Unité 830, Paris, France
    Int J Cancer 122:1778-86. 2008
    ..Finally, our results highlight the potential of a whole-genome analysis as an additional diagnostic in cases of unclear conventional genetic findings...
  17. ncbi TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors
    Ahmed Idbaih
    INSERM, Unité 711, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Cancer Genet Cytogenet 177:103-7. 2007
    ..This suggests no association between oligodendroglial tumors and the SNP in codon 72 of TP53. Similarly, no correlation was found among the TP53 codon 72 polymorphism and prognosis, p53 expression, and chromosomes 1p and 19q status...
  18. ncbi Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status
    François Ducray
    INSERM, Unité U711, Universite Pierre et Marie Curie Paris VI, Paris, France
    J Neurooncol 88:185-8. 2008
    ..This unusual case report suggests that TMZ warrants further investigation in elderly patients with poor performance status...
  19. ncbi Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression
    Virginie Desestret
    AP HP, Groupe Hospitalier Pitie Salpetriere, Neuropathology Laboratory R Escourolle, 75013, Paris, France
    J Neurooncol 105:219-24. 2011
    ..36%; P = 0.003). These data strongly suggest that INA and IDH1(R132H) mutant protein immunohistochemical analysis is of a great prognostic value in biopsied GC...
  20. ncbi Up-front temozolomide in elderly patients with glioblastoma
    Florence Laigle-Donadey
    Service de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    J Neurooncol 99:89-94. 2010
    ..Eight grade III/IV toxicities (seven hematologic, one gastro-intestinal) were seen, but no treatment-related deaths were observed. These preliminary results support further randomized studies comparing TMZ with RT...
  21. ncbi No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis
    Blandine Boisselier
    INSERM, U711, Biologie des Interactions Neurones and Glie, 75013, Paris, France
    J Neurooncol 94:169-72. 2009
    ..Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma...
  22. ncbi Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas
    Caroline Houillier
    Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Neuro Oncol 12:2-6. 2010
    ..05), whereas LOH on 10q had a significant effect on OS (P = .02). Search for LOH 9p and 10q appears to be a useful complement to analysis of chromosomes 1p-19q in LGGs...
  23. ncbi Genomic changes in progression of low-grade gliomas
    Ahmed Idbaih
    INSERM Unité 711, Paris, France
    J Neurooncol 90:133-40. 2008
    ..21%). Interestingly, putative novel candidate genes associated with glioma progression were identified, in particular DOCK8, PTPRD, CER1, TPHO, DHFR, MSH3, ETS1, ACACA, and CSE1L...
  24. ncbi Detection of IDH1 mutation in the plasma of patients with glioma
    Blandine Boisselier
    Universite Pierre et Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moëlle épinière CRICM UMR S975, Paris, France
    Neurology 79:1693-8. 2012
    ..Here, we developed a new technique to detect the IDH1(R132H) mutation in the plasma of patients with glioma...
  25. ncbi Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
    François Ducray
    Unite Inserm U711, Universite Paris VI, 47 83 boulevard de l Hopital, 75013 Paris, France
    Mol Cancer 7:41. 2008
    ..We performed a microarray gene expression study of four high grade gliomas with 1p19q codeletion and nine with EGFR amplification, identified by CGH-array...
  26. ncbi FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status
    Gentian Kaloshi
    Service de Neurologie Mazarin, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, and INSERM, U711, Biologie des Interactions Neurones and Glie, Faculte de Medecine, Universite Pierre et Marie Curie, Paris, Cedex 13, 75651, France
    J Neurooncol 84:245-8. 2007
    ....
  27. ncbi Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
    Julien Laffaire
    Universite Pierre et Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moëlle épinière CRICM UMR S975, 75013 Paris, France
    Neuro Oncol 13:84-98. 2011
    ..Finally, we identified several hypermethylated and downregulated genes that may be associated with LGG and GBM oncogenesis, LGG oncogenesis, 1p19q codeleted LGG oncogenesis, and GBM oncogenesis...
  28. ncbi Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas
    Ahmed Idbaih
    Institut National de la Sante et de la Recherche Medicale, U711, Universite Pierre et Marie Curie, Hopital Pitie Salpetriere, Paris, France
    Neuro Oncol 10:540-7. 2008
    ....
  29. ncbi Loss of 14q chromosome in oligodendroglial and astrocytic tumors
    Charles Dichamp
    , Paris, France
    J Neurooncol 67:281-5. 2004
    ..Loss of 14q was not correlated to survival, histological grading and subtype or other genetic alterations, except for 1p deletions. Taken together, these data suggest that LOH14q is an early alteration involving 20% of glioma...
  30. ncbi Association of telomerase gene hTERT polymorphism and malignant gliomas
    Catherine Carpentier
    INSERM, U711, Biologie des Interactions Neurones and Glie, Universite Pierre et Marie Curie, Faculte de Medecine, and Service de Neurologie Mazarin, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris 13, France
    J Neurooncol 84:249-53. 2007
    ..The MNS16A polymorphism is located in the downstream region of the hTERT gene and affects telomerase activity...
  31. ncbi Prognostic stratification of patients with anaplastic gliomas according to genetic profile
    Caroline Dehais
    INSERM U711, Biologie des Interactions Neurones et Glie, Paris, France
    Cancer 107:1891-7. 2006
    ..CONCLUSIONS: The search for 1p19q codeletion and EGFR receptor amplification provides a simple, clinically relevant prognostic subclassification of grade III gliomas...
  32. ncbi Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas
    Ahmed Idbaih
    INSERM, Unité U711, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Cancer Genet Cytogenet 176:121-6. 2007
    ..Although familial and sporadic gliomas share very similar cytogenetic quantitative patterns, aCGH is a promising technique for the detection of small genomic differences of potential significance...
  33. ncbi Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
    Ahmed Idbaih
    INSERM, U975, Université Pierre and Marie Curie Paris VI, Faculté de Médecine Pitié Salpêtrière, CNRS UMR 7225, Paris, France
    J Neurooncol 103:221-30. 2011
    ..Whole genome analysis appears useful to screen the numerous genomic abnormalities observed in AOTs and to propose new biomarkers particularly in the non-1p/19q codeleted AOTs...
  34. ncbi Prognostic markers in gliomas
    Marianne Labussiere
    Pierre et Marie Curie University Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moëlle épinière CRICM UMR S975, Paris, France
    Future Oncol 6:733-9. 2010
    ..Routine use of these markers considerably contributes to a more objective classification of gliomas based on both histological and molecular features...
  35. ncbi Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
    Gentian Kaloshi
    AP HP, Université Pierre et Marie Curie UPMC, Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Neurooncol 100:439-41. 2010
    ....
  36. ncbi Dynamic history of low-grade gliomas before and after temozolomide treatment
    Damien Ricard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 61:484-90. 2007
    ..To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations...
  37. ncbi Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
    Alexandre Carpentier
    Department of Neurosurgery, Hopital Lariboisiere, Paris, France
    Neuro Oncol 12:401-8. 2010
    ..The molecular or clinical characteristics of a subgroup of patients that could potentially benefit from such an approach remain to be defined...
  38. ncbi Loss of 22q chromosome is related to glioma progression and loss of 10q
    Florence Laigle-Donadey
    , , , 75013, Paris, France
    J Neurooncol 76:265-8. 2006
    ..02). LOH22q was correlated to 10q loss but not to 1p or 9p loss. Taken together, these data suggest that LOH22q is an alteration associated with malignant progression of gliomas...
  39. ncbi NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas
    Magdalena Benetkiewicz
    INSERM, Unité 830, Paris, France
    PLoS ONE 4:e4107. 2009
    ..As such this paper provides clear evidence that the NOTCH2 gene is not physically rearranged by t(1;19) translocation of oligodendroglioma tumors...
  40. ncbi Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature
    Sophie Taillibert
    , , , 75651, Paris, Cedex 13, France
    J Neurooncol 76:201-5. 2006
    ..Up-front chemotherapy benefit to some patients and may be preferred to whole brain radiotherapy. However, the many bias of such retrospective heterogeneous data claim for multicentric clinical trials in this rare disease...
  41. ncbi Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria
    Jaime Gallego Perez-Larraya
    Service de neurologie 2, Division Mazarin, Groupe Hospitalier Pitie Salpetriere, APHP, Universite Pierre et Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, UMR S975, Paris, France
    Neuro Oncol 14:667-73. 2012
    ..The 1-dimensional approach appeared to be as valid as the 2-dimensional approach...
  42. ncbi A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
    Soufiane El Hallani
    UMR975, Hopital de la Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Brain 133:973-82. 2010
    ..We describe here a new mechanism of alternative glioblastoma vascularization and open a new perspective for the antivascular treatment strategy...
  43. ncbi COLD PCR HRM: a highly sensitive detection method for IDH1 mutations
    Blandine Boisselier
    Universite Pierre et Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moëlle épinière CRICM UMR S975, Paris, France
    Hum Mutat 31:1360-5. 2010
    ..In summary, COLD PCR HRM analysis is 100-fold more sensitive than Sanger sequencing, rendering this rapid and powerful strategy particularly useful for samples highly contaminated with normal tissue...
  44. ncbi Two types of chromosome 1p losses with opposite significance in gliomas
    Ahmed Idbaih
    , , Institut Curie, Paris, France
    Ann Neurol 58:483-7. 2005
    ..0001), the second type has a pejorative prognostic value. Complete 1p-arm evaluation therefore is required to appreciate the real clinical significance of 1p loss in gliomas...
  45. ncbi Prognostic value of allelic losses and telomerase activity in meningiomas
    Pascal Leuraud
    Laboratoire de Biologie des Interactions Neurones-Glie, , Service de Neurochirurgie, , , Paris, France
    J Neurosurg 100:303-9. 2004
    ..000512, respectively). CONCLUSIONS: On the basis of these data the authors suggest that LOH analysis and a telomerase activity assay could be useful to determine molecular predictors of outcome in patients with meningiomas...
  46. ncbi Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors
    Lucinda Aguirre-Cruz
    INSERM U495, Laboratoire de Biologie des Interactions Neurones-Glie, Paris, France
    J Neurooncol 67:265-71. 2004
    ..Because Olig genes have a crucial role in oligodendroglial determination, our data could be of help in defining the real spectrum of oligodendroglial tumors...
  47. ncbi Chromosome 7p11.2 (EGFR) variation influences glioma risk
    Marc Sanson
    Universite Pierre et Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de la Moëlle épinière UMR S975, GH Pitié Salpétrière, 47 Boulevard de l Hopital, Paris, France
    Hum Mol Genet 20:2897-904. 2011
    ..These findings show that variation in 7p11.2 is a determinant of inherited glioma risk...
  48. ncbi Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations
    Pascal Leuraud
    , Laboratoire de Biologie des Interactions Neurones-Glie, , AP-HP, Paris, France
    Cancer Res 64:4648-53. 2004
    ..These results suggest that the combined use of histology and molecular markers should eventually be helpful selecting the most appropriate agents for treatment of malignant oligodendrogliomas and astrocytomas...
  49. ncbi Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis
    François Ducray
    Service de Neurologie Mazarin, APHP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Neuro Oncol 10:1035-9. 2008
    ..Its diagnosis is important in order to avoid inappropriate treatment and useless or dangerous spinal root biopsies...
  50. ncbi Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Alexandre Carpentier
    Department of Neurology, , Paris, France
    Neuro Oncol 8:60-6. 2006
    ..2 months. In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma. Main side effects were limited to transient worsening of neurological condition and fever...
  51. ncbi Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas
    Xiao Wei Wang
    CRicm, Pierre and Marie Curie University, Paris, France Inserm U 975, Paris, France UMR 7225, CNRS, Paris, France
    Cancer 119:806-13. 2013
    ..The SNP rs11554137 is independent of the occurrence of somatic mutation on IDH1 codon 132, but, per se, has a prognostic impact in malignant gliomas. Cancer 2013. © 2012 American Cancer Society...
  52. ncbi Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri
    Elie Louis
    , , Paris, France
    Neurology 60:151. 2003
  53. ncbi Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma
    Mathieu Rodero
    Laboratoire d Immunologie Cellulaire, L Institut National de Santé et de Recherche Médicale U543, Paris, France
    J Clin Oncol 26:5957-64. 2008
    ..We hypothesized that genetic polymorphisms in chemokines and their receptors, which together control microglial cell mobilization, may influence survival...
  54. ncbi [Therapeutic strategies and prospects of gliomas]
    Sophie Taillibert
    , , , , 75013, Paris
    Presse Med 33:1278-83. 2004
    ..Chemotherapy has a modest efficacy in glioblastomas, whereas oligodendrogliomas with 1p 19q deletion are chemosensitive tumors...
  55. ncbi [Current classification of gliomas]
    Sophie Taillibert
    , , , , 75013, Paris
    Presse Med 33:1274-7. 2004
    ..Newly identified good prognostic markers (1p and 19q loss in oligodendrogliomas) and new molecular techniques such as microarray may further refine the existing classification...
  56. ncbi Brain lymphoma: usefulness of the magnetic resonance spectroscopy
    Sophie Taillibert
    Department of Neuro Oncology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, Paris, France
    J Neurooncol 86:225-9. 2008
    ..The case we report here illustrates the contribution of magnetic resonance spectroscopy in the diagnostic approach of a very atypical PCNSL...
  57. ncbi Parental 19q loss and PEG3 expression in oligodendrogliomas
    Oriane Trouillard
    , , , 75013 Paris, France
    Cancer Genet Cytogenet 151:182-3. 2004
  58. ncbi Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors
    Agustí Alentorn
    Centre de Recherche de l Institut du Cerveau et Moelle épinière, Institut National de Santé et de Recherche Médicale Unité Mixte de Recherche Scientifique 975 Centre National de Recherche Scientifique and Unité Mixte de Recherche 7225 Université Pierre et Marie Curie, Paris, 75013, France
    Expert Rev Mol Diagn 12:265-77. 2012
    ..These chromosome imbalances provide a promising insight into potential targets for innovative drugs and new interesting diagnostic and prognostic biomarkers for clinical practice...
  59. ncbi Leptomeningeal metastases from solid malignancy: a review
    Sophie Taillibert
    , , , , 75013, Paris, France
    J Neurooncol 75:85-99. 2005
    ..The overall prognosis remains grim and quality of life should remain the priority when deciding which treatment option to apply. However, a sub-group of patients, tentatively defined here, may benefit from an aggressive treatment...
  60. ncbi Intra-cerebral schwannoma simulating glioma
    Elie Louis
    , , Paris, France
    J Neurooncol 64:279-82. 2003
    ....
  61. ncbi Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas
    Marc Sanson
    , Paris, France
    Ann Neurol 52:105-7. 2002
    ....
  62. ncbi [The genetics of glioma: molecular classification]
    Sophie Taillibert
    , , , , 75013 Paris
    Presse Med 33:1268-73. 2004
    ..Genetic profile is not only of diagnostic--but also prognostic relevance, as shown by 1p associated to 19q loss in oligodendrogliomas which is predictive of better prognosis and higher response rate...
  63. ncbi [Systemic metastases of malignant gliomas]
    Maryam Fourtassi
    Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 83, Bd de l Hopital, 75013 Paris
    Bull Cancer 95:522-5. 2008
    ..Metastases from the anaplastic oligodendroglioma which displayed 1p and 19q chromosome codeletion, responded to chemotherapy and the patient survived 8 months...
  64. ncbi [Towards a molecular classification of gliomas]
    Khe Hoang-Xuan
    Service de Neurologie Mazarin, Laboratoire de Neuropathologie R Escourolle, INSERM U495, CHU Pitie Salpetriere, 47 bd de l Hopital, 75651 Paris Cedex 13
    Bull Cancer 92:310-6. 2005
    ..This review discusses recent molecular advances and clinical implications with special focus on oligodendroglial tumors...
  65. ncbi Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri
    G Kaloshi
    Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Neurology 70:590-5. 2008
    ..Because 1p19q codeletion and methylguanine methyl transferase promoter (MGMTP) methylation have been correlated with chemosensitivity of gliomas, their value was investigated in a cohort of patients with GC treated with TMZ...
  66. ncbi Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
    K Hoang-Xuan
    Federation Neurologique Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Clin Oncol 22:3133-8. 2004
    ..To determine the response rate of low-grade oligodendroglial tumors (LGOT) to temozolomide (TMZ) as initial treatment and to evaluate the predictive value of chromosome 1p deletion on the radiologic response...
  67. ncbi OLIG-1 and 2 gene expression and oligodendroglial tumours
    Khe Hoang-Xuan
    Laboratoire de Biologie des Interactions Neurone Glie, INSERM U495, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Neuropathol Appl Neurobiol 28:89-94. 2002
    ..Initial work suggests that this is probably not the case. However further in vitro and in vivo studies analysing the functional consequence of OLIG overexpression in terms of proliferation and tumour progression are needed...
  68. ncbi Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome
    G Kaloshi
    Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris Cedex 13, France
    Neurology 68:1831-6. 2007
    ..To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy...
  69. ncbi Glioblastomas with an oligodendroglial component: a pathological and molecular study
    J He
    Biologie des Interactions Neurone-Glie, INSERM U495 et Universite P. et M. Curie, Paris, France
    J Neuropathol Exp Neurol 60:863-71. 2001
    ..These results suggest that GBMO might represent a subgroup of tumors of oligodendroglial origin that is distinct from the "standard" GBM in terms of tumorigenesis pathway...
  70. ncbi Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
    K Hoang-Xuan
    Biologie des Interactions Neurone glie, INSERM U495 et Université P et M Curie, Federation Neurologique Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris
    Neurology 57:1278-81. 2001
    ..To identify different genetic molecular profiles in oligodendrogliomas and to evaluate their prognostic significance...
  71. ncbi [Neurofibromatosis 1: recommendations for management]
    S Pinson
    Hopital Edouard Herriot, Lyon, France
    Arch Pediatr 9:49-60. 2002
    ..A co-ordinated follow-up in specialised multidisciplinary centres, providing patients with a rational management, is recommended...
  72. ncbi NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype
    Eric Pasmant
    UMR745 INSERM, Universite Paris Descartes, Faculte des Sciences Pharmaceutiques et Biologiques, 4 av de l Observatoire, 75006, Paris, France
    Hum Mutat 31:E1506-18. 2010
    ..High-resolution array-CGH identified a new recurrent approximately 1.0 Mb microdeletion type, designated as type-3, with breakpoints in the paralogous regions middle NF1-REP-b and distal NF1-REP-c...
  73. ncbi Palliative care in patients with primary brain tumors
    Sophie Taillibert
    Service de Neurologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Curr Opin Oncol 16:587-92. 2004
    ..This review updates available data on supportive care in patients with brain tumor...
  74. ncbi [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas]
    F Laigle-Donadey
    Service de Neurologie Mazarin, Groupe Hospitalier de la Pitié Salpêtrière, Paris, France
    Bull Cancer 96:291-7. 2009
    ..For this reason, in the future a more precise understanding of gliomagenesis is needed for a better molecular stratification of patients...
  75. ncbi Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice
    P Leuraud
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, , Paris, France
    Br J Cancer 89:2327-32. 2003
    ..This represents the first step to improve our understanding of the correlations between molecular alterations and response to standard or experimental therapies...
  76. ncbi EGFR tyrosine kinase domain mutations in human gliomas
    Y Marie
    , Paris, France
    Neurology 64:1444-5. 2005
    ..No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib...
  77. ncbi Progressive multifocal leukoencephalopathy mimicking cerebral vasculitis in systemic granulomatosis
    Benjamin Terrier
    Department of Infectious Diseases, Universite Pierre et Marie Curie, APHP, Service de Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Infect 54:e133-5. 2007
    ..In the presence of central neurological symptoms occurring during systemic granulomatosis before specific therapy, PML should be evoked...
  78. ncbi Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma
    A Idbaih
    INSERM, Unité 711, Paris, France
    Neuropathol Appl Neurobiol 35:208-13. 2009
    ..Novel missense mutations of the epidermal growth factor receptor (EGFR) extracellular domain have been recently described in a large series of glioblastomas...
  79. ncbi Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri
    G Kaloshi
    Service de Neurologie Mazarin, AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Neurology 73:445-9. 2009
    ..GC invades both white matter and gray matter in varying proportions, as reflected by the gray matter index (GMI), i.e., the estimated percentage of gray matter involvement...
  80. ncbi Correlations between molecular profile and radiologic pattern in oligodendroglial tumors
    F Laigle-Donadey
    , , Paris, France
    Neurology 63:2360-2. 2004
    ..01). CONCLUSION: There is a significant correlation between loss of heterozygosity on chromosome 1p and tumor location in oligodendrogliomas, suggesting that subtypes of oligodendrogliomas could derive from site-specific precursors...
  81. ncbi Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification
    K Mokhtari
    Laboratoire de neuropathologie R Escourolle (Pr Hauw, Universite Pierre et Marie Curie, Paris, France
    Neuropathol Appl Neurobiol 31:62-9. 2005
    ..Combined testing of Olig2, 1p status, GFAP and p53 expression may therefore be helpful in refining current classification and providing more homogeneous sets of gliomas for clinical studies...
  82. ncbi Connexin 43-mediated bystander effect in two rat glioma cell models
    Marc Sanson
    Biologie des Interactions Neurones Glie, Unité INSERM U495, Université P et M Curie Hôpital de la Salpêtrière, Paris, France
    Cancer Gene Ther 9:149-55. 2002
    ..Overall, our data provide evidence that the restoration of gap junctional communication may potentiate HSV/tk-based cancer treatment and suggest that this strategy may have wider application in cancer therapy...
  83. ncbi Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    S Taillibert
    Service de Neurologie Mazarin, AP HP, Hopital de la Salpetriere, Paris, France
    Neurology 72:1601-6. 2009
    ..Treatment with a regimen of bevacizumab-irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied...
  84. ncbi All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
    M Labussiere
    UMR 975 INSERM UPMC, Paris, France
    Neurology 74:1886-90. 2010
    ..Recently, the gene encoding the human cytosolic NADPH-dependent isocitrate dehydrogenase (IDH1) was reported frequently mutated in gliomas. Rare mutations were also found in the sequence of the mitochondrial isoform IDH2...
  85. ncbi Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma
    C Carpentier
    INSERM U711, Biologie des Interactions Neurones and Glie, Universite Pierre et Marie Curie, France
    Neurology 67:872-4. 2006
    ..6% vs 165/352 = 46.8%; p = 0.0006) corresponding to an odd ratio of 1.67 (1.24; 2.25). A modest difference in median survival was also associated with the TT genotype...
  86. ncbi Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1
    P Leuraud
    INSERM U495, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    Neurology 60:1820-2. 2003
    ..0001 and p = 0.0006). In multivariate analysis, only LOH10p remained statistically related to telomerase activity, suggesting that the telomerase repressor gene located on 10p15.1 is inactivated in high-grade gliomas...
  87. ncbi Supratentorial low-grade gliomas in older patients
    G Kaloshi
    AP HP, Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Neurology 73:2093-8. 2009
    ..Low-grade gliomas (LGG) are thought to be very rare in elderly patients (>60 years) and have not been thoroughly studied...
  88. ncbi Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study
    M Sanson
    Fédération de Neurologie Mazarin, H pital de la Salpêtrière, Paris, France
    J Neurooncol 50:245-9. 2000
    ..Other toxicities were uncommon and mild. Dose reduction was performed in 5 patients. This study suggests that docetaxel displayed no significant activity in patients with malignant recurrent gliomas...
  89. ncbi TP53 codon 72 polymorphism is associated with age at onset of glioblastoma
    S El Hallani
    INSERM, U711, Biologie des Interactions Neurones and Glie, Paris, France
    Neurology 72:332-6. 2009
    ..Functional single nucleotide polymorphisms (SNP) in codon 72 of TP53 have been shown to be a risk factor, a prognostic marker, and related factor to age at onset in various cancers...
  90. ncbi Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas
    Michele Kujas
    INSERM U711 et Université Pierre et Marie Curie Paris VI, France
    Ann Neurol 58:322-6. 2005
    ..521), indicating a major favorable prognostic role of this genetic alteration in low-grade gliomas...
  91. ncbi [Cerebral tumours in the adult. A real increase]
    Marc Sanson
    Service de Neurologie Mazarin, , 75651 Paris Cedex 13
    Rev Prat 56:1755-6. 2006
  92. ncbi Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
    Carole Soussain
    Department of Hematology, Biostatistics Unit, Centre Rene Huguenin, Saint Cloud, France
    J Clin Oncol 26:2512-8. 2008
    ....
  93. ncbi [Pattern of care of high-grade gliomas]
    Florence Laigle-Donadey
    Service de Neurologie Mazarin, groupe hospitalier La Pitié Salpotrière, 75651 Paris Cedex 13
    Rev Prat 56:1779-86. 2006
    ..This effect was particularly clear for patients with MGMT inactivation in the tumour, confirming here also the impact of molecular biology for future management of gliomas...
  94. ncbi No association of MDM2 SNP309 with risk of glioblastoma and prognosis
    Soufiane El Hallani
    INSERM, U711, Biologie des Interactions Neurones and Glie, Paris 75013, France
    J Neurooncol 85:241-4. 2007
    ..In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor...
  95. ncbi Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line
    Nathalie Auger
    INSERM U612, Research Section, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France
    Mol Cancer Ther 5:2182-92. 2006
    ..The data suggest that the acquisition of resistance to temozolomide in this model resulted from the selection of less differentiated preexistent resistant cells in the parental tumor...
  96. ncbi Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients
    Jean Sébastien Guillamo
    INSERM Unité 421, Faculte de Medecine, Villejuif, France
    Brain 126:152-60. 2003
    ..In conclusion, mortality is high in extra-OPT, particularly in adults, whereas OPT are only exceptionally life-threatening. Radiotherapy of OPT is associated with an important morbidity in NF1...
  97. ncbi Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Martin J van den Bent
    Departments of Neurology and Pathology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 24:2715-22. 2006
    ....
  98. ncbi [Standards, Options and Recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)]
    Didier Frappaz
    , Lyon
    Bull Cancer 90:873-86. 2003
    ....
  99. ncbi Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
    Murielle E L Mauer
    European Organisation for Research and Treatment of Cancer Data Center, Quality of Life Unit, Ave Mounier 83 11, Brussels, Belgium 1200
    J Clin Oncol 25:5731-7. 2007
    ..This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer...
  100. ncbi The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma
    Elodie Vauleon
    INSERM, U711, Biologie des Interactions Neurones and Glie, 75651 Paris Cedex 13, France
    Cancer Genet Cytogenet 172:33-7. 2007
    ..Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival...
  101. ncbi Mutational analysis of Rac2 in gliomas
    Ahmed Idbaih
    J Neurooncol 87:365-6. 2008